{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:01:56Z","timestamp":1789581716515,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"DOI":"10.1007\/s12072-026-11150-z","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:21:28Z","timestamp":1789572088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["How to apply artificial intelligence (AI) to facilitate and enhance MASH trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9715-6970","authenticated-orcid":false,"given":"Daniel Yan Zheng","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Qiang","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela S.","family":"Allende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Boon Bee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"2","key":"11150_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam M, Fan J-G, Yu M-L, Wong VW-S, Cua IH, Liu C-J, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19(2):261\u2013301","journal-title":"Hepatol Int."},{"key":"11150_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW-S, Yilmaz Y, Duseja A, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169:1017-1032.e2","journal-title":"Gastroenterology"},{"key":"11150_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29:562\u2013573","journal-title":"Nat Med"},{"key":"11150_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","volume":"11","author":"W Li","year":"2026","unstructured":"Li W, Alazawi W, Loomba R. Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis. Lancet Gastroenterol Hepatol. 2026;11:150\u2013162","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11150_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050722","author":"N Pugliese","year":"2025","unstructured":"Pugliese N, Bertazzoni A, Hassan C, Schattenberg JM, Aghemo A. Revolutionizing MASLD: how artificial intelligence is shaping the future of liver care. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17050722","journal-title":"Cancers (Basel)"},{"key":"11150_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/72062","volume":"27","author":"H Su","year":"2025","unstructured":"Su H, Sun Y, Li R, Zhang A, Yang Y, Xiao F, et al. Large language models in medical diagnostics: scoping review with bibliometric analysis. J Med Internet Res. 2025;27: e72062","journal-title":"J Med Internet Res"},{"key":"11150_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2025.106227","volume":"208","author":"N Dutta","year":"2026","unstructured":"Dutta N, Bose K, Syailendra E, Chu L, Gupta P. Vision-language models in diagnostic imaging: review of technical advances, clinical validation, and practical deployment. Int J Med Inform. 2026;208: 106227","journal-title":"Int J Med Inform"},{"key":"11150_CR8","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2026.0321","author":"DYZ Lim","year":"2026","unstructured":"Lim DYZ, Leow WQ, Allende DS, Chan W-K, Wong VW-S, Goh GBB. Adopting AI-assisted digital pathology imaging analysis in MASH histology assessments. Clin Mol Hepatol. 2026. https:\/\/doi.org\/10.3350\/cmh.2026.0321","journal-title":"Clin Mol Hepatol"},{"key":"11150_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u20131321","journal-title":"Hepatology"},{"key":"11150_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N, Bouillot J-L, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751\u20131759","journal-title":"Hepatology"},{"key":"11150_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2011;45:55\u201358","journal-title":"J Clin Gastroenterol"},{"key":"11150_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2025.09.019","volume":"84","author":"C Lackner","year":"2026","unstructured":"Lackner C, Gouw ASH, Avancini Ferreira Alves V, Arola J, Bedossa P, Behling C, et al. Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials. J Hepatol. 2026;84:693\u2013701","journal-title":"J Hepatol"},{"key":"11150_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322\u20131332","journal-title":"J Hepatol."},{"issue":"3","key":"11150_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/jgh.15385","volume":"36","author":"GL-H Wong","year":"2021","unstructured":"Wong GL-H, Yuen P-C, Ma AJ, Chan AW-H, Leung HH-W, Wong VW-S. Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. J Gastroenterol Hepatol. 2021;36(3):543\u2013550","journal-title":"J Gastroenterol Hepatol."},{"key":"11150_CR15","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S0168-8278(25)00410-6","volume":"82","author":"A Blain","year":"2025","unstructured":"Blain A, Rajan A, Resteu A, Wack K, Chng E, Wonders K, et al. OS-095 Comparative analysis and cross-validation of artificial intelligence digital pathology (PathAI AIM-MASH and HistoIndex qFIBS) vs. expert hepatopathologist scoring in MASLD biopsies \u2013 results of the LITMUS study cohort. J Hepatol. 2025;82:S64\u2013S65","journal-title":"J Hepatol."},{"key":"11150_CR16","first-page":"S723","volume":"80","author":"V Gupta","year":"2024","unstructured":"Gupta V, Hou R, Yashiro H, Zhang S, Cordover D, Kim S, et al. MULTIPLE DP\/AI QUANTIFICATION APPROACHES ARE COMPLIMENTARY IN IDENTIFYING HISTOLOGY FEATURES: CROSS SECTIONAL STUDY IN A JAPANESE COHORT. Hepatology. 2024;80:S723","journal-title":"Hepatology."},{"key":"11150_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70258","volume":"45","author":"K Akbary","year":"2025","unstructured":"Akbary K, Noureddin M, Yayun R, Tai D, Boudes P. Development of AI Based Fibrosis Detection Algorithm by SHG\/TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH. Liver Int. 2025;45: e70258","journal-title":"Liver Int."},{"key":"11150_CR18","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1038\/s41591-024-03172-7","volume":"30","author":"JS Iyer","year":"2024","unstructured":"Iyer JS, Juyal D, Le Q, Shanis Z, Pokkalla H, Pouryahya M, et al. AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. Nat Med. 2024;30:2914\u20132923","journal-title":"Nat Med"},{"key":"11150_CR19","unstructured":"TECHNOLOGY \u2014. In: PharmaNest [Internet]. [cited 5 Jul 2026]. Available: https:\/\/www.pharmanest.com\/technology"},{"key":"11150_CR20","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/hep.30986","volume":"71","author":"F Liu","year":"2020","unstructured":"Liu F, Goh GB-B, Tiniakos D, Wee A, Leow W-Q, Zhao J-M, et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71:1953\u20131966","journal-title":"Hepatology"},{"key":"11150_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2025.06.042","volume":"24","author":"Y Ren","year":"2026","unstructured":"Ren Y, Chang JPE, Tai D, Filozof CM, Kleiner DE, Sanyal AJ. Repeatability and reproducibility of artificial imaging-based digital pathology for the evaluation of liver fibrosis. Clin Gastroenterol Hepatol. 2026;24:713\u2013722","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11150_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jhep.2024.11.032","volume":"82","author":"D Abdurrachim","year":"2025","unstructured":"Abdurrachim D, Lek S, Ong CZL, Wong CK, Zhou Y, Wee A, et al. Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH. J Hepatol. 2025;82:898\u2013908","journal-title":"J Hepatol"},{"key":"11150_CR23","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cgh.2022.05.027","volume":"21","author":"GST Soon","year":"2023","unstructured":"Soon GST, Liu F, Leow W-Q, Wee A, Wei L, Sanyal AJ. Artificial intelligence improves pathologist agreement for fibrosis scores in nonalcoholic steatohepatitis patients. Clin Gastroenterol Hepatol. 2023;21:1940-1942.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11150_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-024-03301-2","volume":"31","author":"H Pulaski","year":"2025","unstructured":"Pulaski H, Harrison SA, Mehta SS, Sanyal AJ, Vitali MC, Manigat LC, et al. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31:315\u2013322","journal-title":"Nat Med"},{"key":"11150_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/liv.15768","volume":"44","author":"A Watson","year":"2024","unstructured":"Watson A, Petitjean L, Petitjean M, Pavlides M. Liver fibrosis phenotyping and severity scoring by quantitative image analysis of biopsy slides. Liver Int. 2024;44:399\u2013410","journal-title":"Liver Int"},{"key":"11150_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/HEP.0000000000001360","volume":"83","author":"N Fujiwara","year":"2026","unstructured":"Fujiwara N, Matsushita Y, Tempaku M, Tachi Y, Kimura G, Izuoka K, et al. AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2026;83:575\u2013590","journal-title":"Hepatology"},{"key":"11150_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509","journal-title":"N Engl J Med."},{"key":"11150_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.03.021","author":"JM Schattenberg","year":"2026","unstructured":"Schattenberg JM, Bedossa P, Guy CD, Taub R, Labriola D, Zhang H, et al. Quantitative regression of qFibrosis with resmetirom: exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. J Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.jhep.2026.03.021","journal-title":"J Hepatol"},{"key":"11150_CR29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat Med. 2023;29:392\u2013400","journal-title":"Nat Med"},{"key":"11150_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jhep.2022.06.018","volume":"77","author":"NV Naoumov","year":"2022","unstructured":"Naoumov NV, Brees D, Loeffler J, Chng E, Ren Y, Lopez P, et al. Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. J Hepatol. 2022;77:1399\u20131409","journal-title":"J Hepatol"},{"key":"11150_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-025-00210-7","author":"LV Marins","year":"2025","unstructured":"Marins LV, Pacca AM, Ferreira Campos CF, de Oliveira IM, Maya Monteiro GB, Salviano Diniz e Souza JP, et al. From slide analysis to precision strategy: the pathologist in the artificial intelligence loop for liver disease diagnosis and patient management. Surg Exp Pathol. 2025. https:\/\/doi.org\/10.1186\/s42047-025-00210-7","journal-title":"Surg Exp Pathol"},{"key":"11150_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/jcp-2025-210311","volume":"79","author":"D Windell","year":"2026","unstructured":"Windell D, Magness A, Beyer C, Brears HT, Larkin S, Hobson K, et al. AI portal tract detection and characterisation for a regional analysis of steatosis and inflammation in MASLD, MASH and AIH. J Clin Pathol. 2026;79:169\u2013178","journal-title":"J Clin Pathol"},{"key":"11150_CR33","doi-asserted-by":"publisher","first-page":"S536","DOI":"10.1016\/S0168-8278(25)01469-2","volume":"82","author":"D Allende","year":"2025","unstructured":"Allende D, Belt P, Wilson L, Behling C, Gill R, Guy C, et al. WED-375 Relevant incidental histologic diagnoses in MASLD patients enrolled in the NASH CRN. J Hepatol. 2025;82:S536","journal-title":"J Hepatol."},{"key":"11150_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12072-026-11092-6","volume":"20","author":"H Elangovan","year":"2026","unstructured":"Elangovan H, Akbary K, Rastogi A, Wee A, Soon G, Adams L, et al. The Asian Pacific Association of the Study of the Liver expert survey on artificial intelligence-assisted reporting of liver histopathology in metabolic dysfunction associated fatty liver disease. Hepatol Int. 2026;20:539\u2013549","journal-title":"Hepatol Int"},{"key":"11150_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.17958","volume":"59","author":"CV Schneider","year":"2024","unstructured":"Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024;59:1271\u20131281","journal-title":"Aliment Pharmacol Ther"},{"key":"11150_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101320","volume":"54","author":"JV Lazarus","year":"2025","unstructured":"Lazarus JV, Brennan PN, Mark HE, Alazawi W, Allen AM, Byrne CD, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. Lancet Reg Health Eur. 2025;54: 101320","journal-title":"Lancet Reg Health Eur."},{"key":"11150_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101798","author":"Willem P Brouwer","year":"2026","unstructured":"Brouwer Willem P, Vonghia L, Thiele M, Schattenberg J, Anastasiou F, Beckmann S, et al. Steatotic liver disease trajectory: a holistic EASL guidance on the multidisciplinary approach to screening and patient management\u2606. JHEP Rep. 2026. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101798","journal-title":"JHEP Rep"},{"key":"11150_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, Byrne CD, Chang Y, Gr\u00f8nbaek H, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74:474\u2013482","journal-title":"Hepatology"},{"key":"11150_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000386","volume":"8","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, Byrne CD, Chang Y, Duseja A, et al. The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol Commun. 2024;8: e0386","journal-title":"Hepatol Commun."},{"key":"11150_CR40","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089\u20132099","journal-title":"N Engl J Med"},{"key":"11150_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77447-x","volume":"14","author":"K Lee","year":"2024","unstructured":"Lee K, Mai Y, Liu Z, Raja K, Jun T, Ma M, et al. Criteriamapper: establishing the automatic identification of clinical trial cohorts from electronic health records by matching normalized eligibility criteria and patient clinical characteristics. Sci Rep. 2024;14: 25387","journal-title":"Sci Rep"},{"key":"11150_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68873-8","author":"RB Parikh","year":"2026","unstructured":"Parikh RB, Kolla L, Beothy EA, Ferrell WJ, Laventure B, Guido M, et al. Human-AI teaming to improve accuracy and efficiency of eligibility criteria prescreening for oncology trials: a randomized evaluation trial using retrospective electronic health records. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-68873-8","journal-title":"Nat Commun"},{"key":"11150_CR43","doi-asserted-by":"publisher","first-page":"9074","DOI":"10.1038\/s41467-024-53081-z","volume":"15","author":"Q Jin","year":"2024","unstructured":"Jin Q, Wang Z, Floudas CS, Chen F, Gong C, Bracken-Clarke D, et al. Matching patients to clinical trials with large language models. Nat Commun. 2024;15:9074","journal-title":"Nat Commun."},{"key":"11150_CR44","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ajpath.2022.07.012","volume":"192","author":"P L\u00f3pez-\u00dabeda","year":"2022","unstructured":"L\u00f3pez-\u00dabeda P, Mart\u00edn-Noguerol T, Aneiros-Fern\u00e1ndez J, Luna A. Natural Language Processing in Pathology: Current Trends and Future Insights. Am J Pathol. 2022;192:1486\u20131495","journal-title":"Am J Pathol."},{"key":"11150_CR45","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00330-024-11107-6","volume":"35","author":"F Busch","year":"2025","unstructured":"Busch F, Hoffmann L, Dos Santos DP, Makowski MR, Saba L, Prucker P, et al. Large language models for structured reporting in radiology: past, present, and future. Eur Radiol. 2025;35:2589\u20132602","journal-title":"Eur Radiol"},{"key":"11150_CR46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41591-024-03302-1","volume":"31","author":"R Tanno","year":"2025","unstructured":"Tanno R, Barrett DGT, Sellergren A, Ghaisas S, Dathathri S, See A, et al. Collaboration between clinicians and vision-language models in radiology report generation. Nat Med. 2025;31:599\u2013608","journal-title":"Nat Med."},{"key":"11150_CR47","unstructured":"Oncoshot. [cited 23 Jul 2026]. Available: https:\/\/www.oncoshot.com\/"},{"key":"11150_CR48","unstructured":"Website. Available: US FDA. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. Website: https:\/\/www.fda.gov\/media\/119044\/download. Accessed on 11 June 2026."},{"key":"11150_CR49","unstructured":"Website. Available: Intercept Pharmaceuticals. Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment (REGENERATE). Website: https:\/\/clinicaltrials.gov\/study\/NCT02548351. Accessed on 11 June 2026."},{"key":"11150_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/hep.32545","volume":"77","author":"P Sripongpun","year":"2023","unstructured":"Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, et al. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care. Hepatology. 2023;77:256\u2013267","journal-title":"Hepatology"},{"key":"11150_CR51","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402:988\u2013996","journal-title":"Lancet"},{"key":"11150_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","volume":"167","author":"LA van Kleef","year":"2024","unstructured":"van Kleef LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, Sanchez-Luque CB, Prieto-Ortiz RG, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology. 2024;167:357-367.e9","journal-title":"Gastroenterology"},{"key":"11150_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","volume":"10","author":"KP Lindvig","year":"2025","unstructured":"Lindvig KP, Thorhauge KH, Hansen JK, Kj\u00e6rgaard M, Hansen CD, Johansen S, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10:55\u201367","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11150_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083182","volume":"390","author":"R Strandberg","year":"2025","unstructured":"Strandberg R, \u00c5berg F, Asteljoki JV, Luukkonen PK, Salomaa V, Jula A, et al. Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study. BMJ. 2025;390: e083182","journal-title":"BMJ"},{"key":"11150_CR55","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542","journal-title":"J Hepatol"},{"key":"11150_CR56","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u20131835","journal-title":"Hepatology"},{"key":"11150_CR57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","volume":"83","author":"TC-F Yip","year":"2025","unstructured":"Yip TC-F, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304\u2013314","journal-title":"J Hepatol"},{"key":"11150_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","volume":"79","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Truong E, Mayo R, Mart\u00ednez-Arranz I, Minchol\u00e9 I, Banales JM, et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024;79:135\u2013148","journal-title":"Hepatology"},{"key":"11150_CR59","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8:714\u2013725","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11150_CR60","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.cgh.2025.10.029","volume":"24","author":"K Stefanakis","year":"2026","unstructured":"Stefanakis K, Mingrone G, George J, Mantzoros CS. Novel machine-learning models outperform noninvasive tests in metabolic dysfunction-associated steatohepatitis with fibrosis. Clin Gastroenterol Hepatol. 2026;24:1836\u20131853","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11150_CR61","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14309\/ajg.0000000000003432","volume":"121","author":"N Alkhouri","year":"2026","unstructured":"Alkhouri N, Cheuk-Fung Yip T, Castera L, Takawy M, Adams LA, Verma N, et al. ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease. Am J Gastroenterol. 2026;121:362\u2013374","journal-title":"Am J Gastroenterol"},{"key":"11150_CR62","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jhep.2025.07.003","volume":"83","author":"J Clusmann","year":"2025","unstructured":"Clusmann J, Balaguer-Montero M, Bassegoda O, Schneider CV, Seraphin T, Paintsil E, et al. The barriers to uptake of artificial intelligence in hepatology and how to overcome them. J Hepatol. 2025;83:1410\u20131426","journal-title":"J Hepatol"},{"key":"11150_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04348-9","volume":"23","author":"A Lin","year":"2025","unstructured":"Lin A, Wang Z, Jiang A, Chen L, Qi C, Zhu L, et al. Large language models in clinical trials: applications, technical advances, and future directions. BMC Med. 2025;23: 563","journal-title":"BMC Med"},{"issue":"3","key":"11150_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000367","volume":"8","author":"F Pradhan","year":"2024","unstructured":"Pradhan F, Fiedler A, Samson K, Olivera-Martinez M, Manatsathit W, Peeraphatdit T. Artificial intelligence compared with human-derived patient educational materials on cirrhosis. Hepatol Commun. 2024;8(3): e0367. https:\/\/doi.org\/10.1097\/HC9.0000000000000367","journal-title":"Hepatol Commun."},{"key":"11150_CR65","doi-asserted-by":"publisher","DOI":"10.47912\/jscdm.438","author":"A Ghosh","year":"2025","unstructured":"Ghosh A, Huang CJ. Leveraging ChatGPT to streamline clinical trial data administration: Balancing efficiency with ethical responsibility. J Soc Clin Data Manag. 2025. https:\/\/doi.org\/10.47912\/jscdm.438","journal-title":"J Soc Clin Data Manag."},{"key":"11150_CR66","doi-asserted-by":"publisher","first-page":"1201419","DOI":"10.3389\/fddsv.2023.1201419","volume":"3","author":"N Singh","year":"2023","unstructured":"Singh N, Vayer P, Tanwar S, Poyet J-L, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Front Drug Discov. 2023;3:1201419","journal-title":"Front Drug Discov."},{"key":"11150_CR67","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2009","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2009;323:844\u2013853","journal-title":"JAMA"},{"key":"11150_CR68","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med. 2025;31:2602\u20132610","journal-title":"Nat Med"},{"key":"11150_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.914017","volume":"14","author":"FW Pun","year":"2022","unstructured":"Pun FW, Liu BHM, Long X, Leung HW, Leung GHD, Mewborne QT, et al. Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics \u2013 An AI-Enabled Biological Target Discovery Platform. Front Aging Neurosci. 2022;14: 914017","journal-title":"Front Aging Neurosci."},{"key":"11150_CR70","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","volume":"43","author":"F Ren","year":"2025","unstructured":"Ren F, Aliper A, Chen J, Zhao H, Rao S, Kuppe C, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2025;43:63\u201375","journal-title":"Nat Biotechnol"},{"key":"11150_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709856","volume":"12","author":"DP Smith","year":"2021","unstructured":"Smith DP, Oechsle O, Rawling MJ, Savory E, Lacoste AMB, Richardson PJ. Expert-augmented computational drug repurposing identified Baricitinib as a treatment for COVID-19. Front Pharmacol. 2021;12: 709856","journal-title":"Front Pharmacol"},{"key":"11150_CR72","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407\u20131418","journal-title":"Lancet Respir Med"},{"key":"11150_CR73","unstructured":"[cited 4 Jul 2026]. Available: https:\/\/www.justice.gov\/usao-edwa\/pr\/richland-business-owner-sentenced-more-28-years-federal-prison-falsifying-human"},{"key":"11150_CR74","unstructured":"Website. Available: https:\/\/www.bmj.com\/content\/371\/bmj.m3946"},{"key":"11150_CR75","unstructured":"Piller C. Alzheimer\u2019s drug developers accuse clinical trial sites of faking data. [cited 4 Jul 2026]. Available: https:\/\/www.science.org\/content\/article\/alzheimer-s-drug-developers-accuse-clinical-trial-sites-faking-data"},{"key":"11150_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/alz70859_103051","volume":"21","author":"J Geraci","year":"2025","unstructured":"Geraci J, O\u2019Keefe PP, Qorri B, Leonchyk P, Alphs L, Pani L, et al. Detecting Site-Level Fraud via an Artificial Intelligence\/Machine Learning Paradoxical Patient Analysis in an Alzheimer\u2019s Disease Clinical Trial. Alzheimer\u2019s & Dementia. 2025;21: e103051","journal-title":"Alzheimer\u2019s & Dementia."},{"key":"11150_CR77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s43441-026-00950-y","volume":"60","author":"P Tiikkainen","year":"2026","unstructured":"Tiikkainen P, Collin F, Koneswarakantha B. Enhancing data quality in clinical trials: cross-company validation of the open-source clinical trial anomaly spotter (CTAS). Ther Innov Regul Sci. 2026;60:643\u2013653","journal-title":"Ther Innov Regul Sci"},{"key":"11150_CR78","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41409-024-02324-0","volume":"59","author":"G Li","year":"2024","unstructured":"Li G, Chen Y-B, Peachey J. Construction of a digital twin of chronic graft vs. host disease patients with standard of care. Bone Marrow Transplant. 2024;59:1280\u20131285","journal-title":"Bone Marrow Transplant"},{"key":"11150_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101219","volume":"7","author":"PLH Yu","year":"2025","unstructured":"Yu PLH, Chiu KW-H, Lu J, Lui GCS, Zhou J, Cheng H-M, et al. Application of a deep learning algorithm for the diagnosis of HCC. JHEP Rep. 2025;7: 101219","journal-title":"JHEP Rep"},{"issue":"2","key":"11150_CR80","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/HEP.0000000000001180","volume":"82","author":"RW-H Hui","year":"2025","unstructured":"Hui RW-H, Chiu KW-H, Lee I-C, Wang C, Cheng H-M, Lu J, et al. Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery. Hepatology. 2025;82(2):344\u2013356","journal-title":"Hepatology."},{"key":"11150_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101752","volume":"8","author":"D Abdurrachim","year":"2026","unstructured":"Abdurrachim D, Wee A, Soon G, Idowu M, Kendall TJ, Lek S, et al. AI-assisted fibrosis scoring in MASH: exploring pathologist decision-making with an SHG-based AI digital pathology tool. JHEP Rep. 2026;8: 101752","journal-title":"JHEP Rep"},{"key":"11150_CR82","unstructured":"Generating Evidence for Artificial Intelligence Based Medical Devices: A Framework for Training Validation and Evaluation. World Health Organization; 17 Nov 2021 [cited 4 Jul 2026]. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240038462"},{"key":"11150_CR83","unstructured":"Website. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological#:~:text=This%20guidance%20provides%20recommendations%20to,COU"},{"key":"11150_CR84","doi-asserted-by":"crossref","unstructured":"E. Beede, E. Baylor, F. Hersch, A. Iurchenko, L. Wilcox, P. Ruamviboonsuk, et al. 2020 A human-centered evaluation of a deep learning system deployed in clinics for the detection of diabetic retinopathy. Proceedings of the CHI Conference on Human Factors in Computing Systems. New York, NY, USA: ACM; 2020. pp. 1\u201312.","DOI":"10.1145\/3313831.3376718"},{"key":"11150_CR85","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1016\/S2214-109X(25)00473-5","volume":"14","author":"P Song","year":"2026","unstructured":"Song P, Jiang D, Zhou J, Zhu Y, Manaf RA, Bojude DA, et al. Research priorities for data science and artificial intelligence in global health: an international consensus exercise. Lancet Glob Health. 2026;14:e455\u2013e465","journal-title":"Lancet Glob Health"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11150-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:47Z","timestamp":1789578167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":85,"alternative-id":["11150"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11150-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr WK Seto received speaker\u2019s fees from Echosens and Merck Sharp & Dohme, is an advisory board member of Novo Nordisk, is an advisory board member and received speaker fees from Gilead Sciences, and received research funding via The University of Hong Kong from 89Bio, AstraZeneca, Boehringer Ingelheim, Pfizer and Ribo Life Sciences. Dr TCF Yip has served as an advisor for Altimmune, Gilead Sciences, and GSK, and a speaker for Gilead Sciences and Echosens Dr GBB Goh served as a consultant for MSD, Novo Nordisk, Boehringer Ingelheim and Kowa; and a speaker for Echosens, Viatris, Abbott and Novo Nordisk.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}